This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Peer-Reviewed Publication Demonstrates Patient Safety Aspects Of Vision-Sciences' EndoSheath(R) Technology For Flexible Cystoscopes

ORANGEBURG, N.Y., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) announced today the publication of positive outcomes of a clinical study that evaluated the durability and microbial barrier properties of the Company's EndoSheath ® technology in the flexible cystoscopy setting in the November issue of the peer-reviewed journal BMC Urology.

To assess the efficacy of Vision-Sciences' EndoSheath technology with flexible cystoscopes, study authors tested the barrier integrity of each EndoSheath disposable following clinical procedures and then performed microbiology sampling of the flexible cystoscopes to determine if any bacterial contamination had occurred. Study outcomes and conclusions include:
  • 100% of EndoSheath units tested were leak-free following clinical use. This finding confirms outcomes of a prior study of 875 endoscopic procedures in which no leaks were reported.  
  • 100% of microbiology samples showed a clean flexible cystoscope following EndoSheath technology usage and the Company's recommended cleaning procedure.  
  • The study authors concluded that Vision-Sciences' reprocessing procedure featured a low risk of pathogen transmission, high-patient safety and a valid alternative to the recommended high-level disinfection procedure of competitive flexible cystoscopes.

"This was the first research to assess the microbiology and sheath integrity of our EndoSheath technology in the cystoscopy setting. These highly positive results demonstrate that the EndoSheaths did not break, and that the use of our EndoSheath technology followed by our three-step cleaning process has a low risk of pathogen transmission and high patient safety. This supports our longstanding position that the EndoSheath technology provides an 'always ready, always sterile' endoscope," said Howard Zauberman, Vision-Sciences' Interim Chief Executive Officer.

The study, entitled "A microbiological evaluation of level of disinfection for flexible cystoscopes protected by disposable endosheaths," was conducted by researchers in Denmark at the Frederiksberg University Hospital, Hvidovre University Hospital, and University of Copenhagen. Microbiological samples from 100 cystoscopies performed with flexible cystoscopes ("FC") using disposable sterile EndoSheaths were obtained twice: after removal of the EndoSheath, and after cleaning the scope with a detergent cloth, rinsing with tap water followed by 70% ethanol disinfection, and subsequent drying. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs